Vaccinex (VCNX) Cut to Sell at Zacks Investment Research

Zacks Investment Research lowered shares of Vaccinex (NASDAQ:VCNX) from a hold rating to a sell rating in a research note issued to investors on Thursday morning.

According to Zacks, “Vaccinex, Inc. is a clinical-stage immunotherapy company. It engages in the discovery and development of biotherapeutics to treat serious diseases and conditions with unmet medical needs, including cancer, neurodegenerative diseases and autoimmune disorders. The company’s product pipeline consists of VX15, VX5 and VX25 which are in clinical stage. Vaccinex, Inc. is based in Rochester, New York. “

Several other equities research analysts have also weighed in on VCNX. BTIG Research initiated coverage on shares of Vaccinex in a report on Tuesday, September 4th. They issued a buy rating on the stock. Oppenheimer initiated coverage on shares of Vaccinex in a report on Tuesday, September 4th. They issued a buy rating and a $22.00 target price on the stock. Finally, LADENBURG THALM/SH SH initiated coverage on shares of Vaccinex in a report on Tuesday, September 4th. They issued a buy rating and a $22.00 target price on the stock.

VCNX opened at $5.59 on Thursday. Vaccinex has a twelve month low of $5.10 and a twelve month high of $12.00.

Vaccinex (NASDAQ:VCNX) last posted its earnings results on Tuesday, November 13th. The company reported ($0.93) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.64) by ($0.29). The business had revenue of $0.20 million for the quarter. Research analysts forecast that Vaccinex will post -4.46 EPS for the current year.

Institutional investors and hedge funds have recently bought and sold shares of the business. Vanguard Group Inc. acquired a new stake in Vaccinex in the third quarter worth $341,000. Perceptive Advisors LLC acquired a new stake in Vaccinex in the third quarter worth $365,000. Bank of New York Mellon Corp acquired a new stake in Vaccinex in the third quarter worth $124,000. Finally, Nexthera Capital LP acquired a new stake in Vaccinex in the third quarter worth $124,000. Institutional investors own 0.17% of the company’s stock.

About Vaccinex

Vaccinex, Inc operates as a clinical-stage biotechnology company. It engages in the discovery and development of bio therapeutics to treat serious diseases and conditions with unmet medical needs, including cancer, neurodegenerative diseases, and autoimmune disorders. Its lead product candidate is VX15 that is in Phase Ib/II clinical trials for the treatment of advanced solid tumors, including non-small cell lung cancer, osteosarcoma, and melanoma; and Phase II clinical trials for the treatment of Huntington's disease.

Recommended Story: Benefits of owning preferred stock

Get a free copy of the Zacks research report on Vaccinex (VCNX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Vaccinex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vaccinex and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit